Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 2:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sildenafil citrate Clear all
Terminated Phase 3 Interventional Results available

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

NCT00795639
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Sitaxsentan, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 80 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Fountain Valley, California • Mather, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Sep 29, 2026, 2:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)

NCT05684289
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986278, Sildenafil, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
35 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 29, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)

NCT00763867
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Sildenafil
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Sep 29, 2026, 2:00 AM EDT
Terminated Phase 1 Interventional

Sildenafil to Treat HIV-Associated Pulmonary Hypertension

NCT00327080
View directory record Official record
Conditions
HIV
Interventions
MRI, L-NMMA, Acetylcholine
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 29, 2026, 2:00 AM EDT
Recruiting Phase 2 Interventional

Sildenafil for Early Pulmonary Vascular Disease in Scleroderma

NCT04797286
View directory record Official record
Conditions
Scleroderma, Mildly Elevated Pulmonary Pressures
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 29, 2026, 2:00 AM EDT
Completed Not applicable Interventional Results available

Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus

NCT00478335
View directory record Official record
Conditions
Nephrogenic Diabetes Insipidus
Interventions
sildenafil, calcitonin, hydrochlorothiazide/amiloride, indomethacin, Placebo for sildenafil, placebo for calcitonin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 25 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Sep 29, 2026, 2:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Taste Test of a New Formulation of Sildenafil (Revatio)

NCT00768573
View directory record Official record
Conditions
None Volunteer
Interventions
sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 29, 2026, 2:00 AM EDT
Completed No phase listed Observational

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

NCT00000623
View directory record Official record
Conditions
Anemia, Cooley's, Beta-Thalassemia, Hematologic Diseases, Thalassemia, Osteoporosis, Iron Overload, Hypertension, Pulmonary
Interventions
Deferoxamine, Deferiprone, Arginine, Sildenafil, Decitabine
Drug
Lead sponsor
Carelon Research
Other
Eligibility
1 Year to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
4
States / cities
Oakland, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 29, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.

NCT00159913
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Children
Interventions
Sildenafil citrate, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
10
States / cities
Palo Alto, California • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 29, 2026, 2:00 AM EDT
Completed Phase 2 Interventional Results available

The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease

NCT02546609
View directory record Official record
Conditions
NAFLD
Interventions
Leu-Met-Sil 0.5, Leu-Met-Sil 1.0, Placebo
Drug
Lead sponsor
NuSirt Biopharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
13
States / cities
Chino, California • San Diego, California • Wheat Ridge, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 29, 2026, 2:00 AM EDT
Completed Phase 2 Interventional Results available

Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis

NCT00359736
View directory record Official record
Conditions
Alveolitis, Fibrosing, Fibrosis, Pulmonary, Hypertension, Pulmonary
Interventions
sildenafil
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Sep 29, 2026, 2:00 AM EDT
Terminated Phase 2 Interventional

Sildenafil and Pulmonary Artery Pressure

NCT00145938
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
sildenafil
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Sep 29, 2026, 2:00 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Effects of Viagra® Vs Hezkue® in Healthy Fasted Male Participants.

NCT06782659
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
ASP-001, Viagra, ASP-001
Drug · Device
Lead sponsor
Aspargo Labs, Inc
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 29, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH

NCT00159861
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
16 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
33
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 29, 2026, 2:00 AM EDT
Completed Early Phase 1 Interventional

Topical Sildenafil as Pre-Treatment for Hand-Foot Skin Reaction

NCT03229512
View directory record Official record
Conditions
Hand Foot Skin Reaction
Interventions
Sildenafil
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 29, 2026, 2:00 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Non-invasive Measurement of Cerebrovascular Reactivity After Traumatic Brain Injury

NCT02990078
View directory record Official record
Conditions
TBI
Interventions
Sildenafil citrate, Functional Near Infared Spectroscopy, Hypercapnia Challenge
Drug · Device · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Sep 29, 2026, 2:00 AM EDT
Completed No phase listed Observational

Modulating Effects of Lisinopril on Sildenafil Activity in Pulmonary Arterial Hypertension(PAH)( MELISSA)

NCT01181284
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Sep 29, 2026, 2:00 AM EDT
Completed Phase 3 Interventional

Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension

NCT00159887
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
24
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 29, 2026, 2:00 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS

NCT00598585
View directory record Official record
Conditions
Chronic Fatigue Syndrome
Interventions
Sildenafil (Viagra), Placebo
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 49 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Sep 29, 2026, 2:00 AM EDT
Completed Not applicable Interventional Results available

Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula

NCT02414204
View directory record Official record
Conditions
Improve Endothelial Function and Decrease Vascular Stenosis
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Sep 29, 2026, 2:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo

NCT01616485
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
TA-1790, Sildenafil citrate, Placebo, Nitrostat
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
30 Years to 60 Years · Male only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Sep 29, 2026, 2:00 AM EDT
Completed Not applicable Interventional Results available

Nebivolol in the Supine Hypertension of Autonomic Failure

NCT01044693
View directory record Official record
Conditions
Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions
Placebo, Nebivolol 5 mg, metoprolol tartrate 50 mg, Sildenafil25 mg
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Sep 29, 2026, 2:00 AM EDT
Completed Phase 1Phase 2 Interventional

Sildenafil for PNTM Infection

NCT01853540
View directory record Official record
Conditions
Nontuberculous Mycobacterial Infection
Interventions
Sildenafil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Sep 29, 2026, 2:00 AM EDT
Terminated Phase 2 Interventional Results available

Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy

NCT01168908
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Interventions
Sildenafil
Drug
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 29, 2026, 2:00 AM EDT